CCG Wealth Management LLC Buys 172 Shares of Johnson & Johnson $JNJ

CCG Wealth Management LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 11.3% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,691 shares of the company’s stock after purchasing an additional 172 shares during the quarter. CCG Wealth Management LLC’s holdings in Johnson & Johnson were worth $258,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Nuveen LLC bought a new position in Johnson & Johnson in the 1st quarter valued at $1,369,188,000. Bank of New York Mellon Corp grew its position in Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after acquiring an additional 4,842,582 shares during the last quarter. Pacer Advisors Inc. grew its position in Johnson & Johnson by 1,382.0% in the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock valued at $502,509,000 after acquiring an additional 2,825,626 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Johnson & Johnson by 159.6% in the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after acquiring an additional 2,557,388 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new position in Johnson & Johnson in the 2nd quarter valued at $401,420,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.0%

Shares of NYSE:JNJ opened at $190.88 on Wednesday. The business’s 50-day moving average is $179.28 and its 200 day moving average is $164.16. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.40. The firm has a market capitalization of $459.70 billion, a P/E ratio of 20.41, a P/E/G ratio of 2.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $24.02 billion for the quarter. On average, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Analysts Set New Price Targets

JNJ has been the topic of several research analyst reports. Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Barclays upped their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Morgan Stanley upped their target price on Johnson & Johnson from $176.00 to $178.00 and gave the stock an “equal weight” rating in a report on Friday, October 10th. UBS Group upped their target price on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Weiss Ratings upgraded Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $193.88.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.